A committee of Japan's health ministry has approved US biotechnology company Novavax Inc's (Nasdaq:NVAX) COVID-19 vaccine, Reuters news agency reported on Monday.
If granted full approval, this will be Japan's fourth COVID-19 vaccine.
The Japanese government has reportedly agreed to purchase 150 million doses of Novavax's recombinant protein type vaccine, which will be manufactured in Japan by Takeda Pharmaceutical Co (Tokyo:4502).
So far, most of Japan's COVID-19 vaccinations have been carried out with the mRNA vaccines made by US pharmaceutical companies Pfizer Inc (NYSE:PFE) and Moderna Inc (Nasdaq:MRNA).
The vaccine from British pharmaceutical company Astrazeneca plc (LON:AZN) has also been approved, but most domestically produced supplies have not been used in Japan and instead donated overseas.
GSK secures EU approval for fully liquid Menveo vaccine
Scancell reports promising SCOPE trial data for SCIB1 in advanced melanoma
Transgene teams up with ProBioGen for individualised cancer vaccines
Bio-Works Technologies AB secures LOI for vaccine manufacturing product
LakeShore Biopharma's Phase III YSJA Rabies Vaccine clinical trial receives Chinese NMPA approval
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
GSK PLC announces acceptance of NDA for gepotidacin by US FDA